Geode Capital Management LLC boosted its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 1.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 433,420 shares of the biopharmaceutical company’s stock after buying an additional 4,141 shares during the period. Geode Capital Management LLC’s holdings in Lexicon Pharmaceuticals were worth $6,215,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. C WorldWide Group Holding A S raised its stake in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 280 shares in the last quarter. 361 Capital LLC purchased a new stake in Lexicon Pharmaceuticals during the first quarter worth $186,000. Trexquant Investment LP purchased a new stake in Lexicon Pharmaceuticals during the first quarter worth $323,000. Principal Financial Group Inc. raised its stake in Lexicon Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 22,684 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 70 shares in the last quarter. Finally, American International Group Inc. raised its stake in Lexicon Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 26,020 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 1,716 shares in the last quarter.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded down 0.93% during mid-day trading on Wednesday, reaching $14.92. 64,787 shares of the company’s stock traded hands. Lexicon Pharmaceuticals, Inc. has a 12-month low of $13.41 and a 12-month high of $19.62. The firm’s market capitalization is $1.58 billion. The stock has a 50-day moving average price of $16.49 and a 200 day moving average price of $15.38.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.12. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company’s revenue for the quarter was down 40.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.37) EPS. Analysts anticipate that Lexicon Pharmaceuticals, Inc. will post ($1.45) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Geode Capital Management LLC Has $6.22 Million Stake in Lexicon Pharmaceuticals, Inc. (LXRX)” was published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/geode-capital-management-llc-has-6-22-million-stake-in-lexicon-pharmaceuticals-inc-lxrx.html.

A number of analysts have recently weighed in on the stock. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. HC Wainwright set a $27.00 target price on shares of Lexicon Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 3rd. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average target price of $27.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.